winner

• ShiftPixy, Inc. PIXY Shares soared 176.5% to close at $31.00 on Thursday after the company announced plans to spin off ShiftPixy Labs and distribute its digital securities to shareholders.
• Amylyx Pharmaceuticals, Inc. AMLX up 51% to $27.03 after the FDA Advisory Committee decided there was sufficient evidence of efficacy to support approval of AMX0035 for the treatment of ALS. Citigroup and SVB Leerink have raised their price targets.
• Rubius Therapeutics, Inc. RUBY up 48.6% to close at $1.29 after falling 11% on Wednesday. Rubius Therapeutics posted a Q2 loss of $0.49 per share last month.
• Benitec Biopharma Inc. BNTC Shares gained 33% to close at $0.7880. The company filed its annual report on Form 10-K for the quarter ended June 30, 2022 with the U.S. Securities and Exchange Commission last week.
• Marker Therapeutics, Inc. MRKR up 31.5% to $0.3999 after the company’s Phase 2 study of multitumor-associated antigen-specific T-cell therapy for relapsed/refractory AML was published on the FDA’s Orphan Products Grants Program website.
• Palatin Technologies, Inc. PTN up 26.2% to $6.31 after the company announced the start of patient enrollment in its Phase 2 study evaluating oral PL8177 in ulcerative colitis.
• LifeStance Health Group, Inc. LFST rose 25.8% to close at $9.57. LifeStance Health named Ken Burdick as CEO and Chairman.
• T Stamp Inc. IDAI gained 25% and traded at $1.85.
• Asana, Inc. ASAN Shares gained 24.8% to close at $23.76 after the company reported better-than-expected second-quarter results and issued strong sales guidance. RBC Capital and Citigroup have both raised their price targets on the stock.
• Relay Therapeutics, Inc. RLAY gained 23.8% to close at $31.37. Relay Therapeutics Announced Efficacy of RLY-4008, a Highly Selective FGFR2 Inhibitor, in Patients With FGFR2 Fusion or Rearrangement FGFR Inhibitor-naïve Cholangiocarcinoma: ReFocus Study.
• Revance Therapeutics,…